Source: EURLEX
Language: en
Format: md

|  |  |  |  |
| --- | --- | --- | --- |
| 28.2.2022 | EN | Official Journal of the European Union | C 95/33 |

---

Judgment of the General Court of 21 December 2021 — Fidia farmaceutici v EUIPO — Stelis Biopharma (HYALOSTEL ONE)

(Case T-194/21) [(1)](#ntr1-C_2022095EN.01003301-E0001)

(EU trade mark - Opposition proceedings - International figurative registration designating the European Union - Figurative mark HYALOSTEL ONE - Earlier EU word mark HYALISTIL and earlier figurative mark HyalOne - Earlier international word mark HYALO - Relative ground for refusal - Article 8(1)(b) of Regulation (EU) 2017/1001 - Obligation to state reasons)

(2022/C 95/45)

Language of the case: English

Parties

Applicant: Fidia farmaceutici SpA (Abano Terme, Italy) (represented by: R. Kunz-Hallstein and H.P. Kunz-Hallstein, lawyers)

Defendant: European Union Intellectual Property Office (represented by: E. Sliwinska and V. Ruzek, acting as Agents)

Other party to the proceedings before the Board of Appeal of EUIPO: Stelis Biopharma Ltd (Karnataka, India)

Re:

Action brought against the decision of the Fifth Board of Appeal of EUIPO of 27 January 2021 (Case R 831/2020-5), relating to opposition proceedings between Fidia Farmaceutici and Stelis Biopharma.

Operative part of the judgment

The Court:

|  |  |
| --- | --- |
| 1. | Annuls the decision of the Fifth Board of Appeal of the European Union Intellectual Property Office (EUIPO) of 27 January 2021 (Case R 831/2020-5); |

|  |  |
| --- | --- |
| 2. | Orders EUIPO to bear its own costs and to pay those incurred by Fidia farmaceutici SpA in connection with the present proceedings. |

---

---

[Top](#document1)